Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
New England Journal of Medicine · 29.05.2025 · 392 (20) · 2001-2012
DOI: 10.1056/nejmoa2501006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 29.05.2025. Verfasst von Darren K McGuire und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas. Hauptthemen laut MEDLINE: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 451-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Texas Southwestern Medical Center, Dallas.
- Parkland Health System, Dallas.
- Clinic for Cardiology, Angiology, and Intensive Care Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, University Hospital Aachen, Aachen, Germany.
- Department of Medicine, Division of Cardiology, Dalhousie University, Halifax, NS, Canada.
- Institute of Cardiovascular Sciences, University College London, London.
- Section of Endocrinology, Yale University School of Medicine, New Haven, CT.
ORCID-Profile: Matthew A Cavender
Förderung
- Novo Nordisk
Zitieren
APA
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., Ripa, M. S., Hovingh, G. K., Brown-Frandsen, K., Bain, S. C., Cavender, M. A., Gislum, M., David, J. P., Buse, J. B., & SOUL Study Group (2025). Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine, 392(20), 2001-2012. https://doi.org/10.1056/nejmoa2501006
Vancouver
McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine. 2025;392(20):2001-2012. doi:10.1056/nejmoa2501006
BibTeX
@article{McGuire2025,
author = {McGuire, Darren K and Marx, Nikolaus and Mulvagh, Sharon L and Deanfield, John E and Inzucchi, Silvio E and Pop-Busui, Rodica and Mann, Johannes F E and Emerson, Scott S and Poulter, Neil R and Engelmann, Mads D M and Ripa, Maria Sejersten and Hovingh, G Kees and Brown-Frandsen, Kirstine and Bain, Stephen C and Cavender, Matthew A and Gislum, Mette and David, Jens-Peter and Buse, John B and SOUL Study Group, SOUL Study Group},
title = {Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {20},
pages = {2001--2012},
doi = {10.1056/nejmoa2501006}
}
EUVIMED